Targeted Nutrient Supplement in COPD (NUTRECOVER-trial)

Prior treatment

• Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;
• Recent hospital admission (\<4 weeks prior to the start of the study);
• Temporary oral steroid or antibiotics use due to a COPD exacerbation in the last 4 weeks;
• Lung malignancy in the previous 5 years;
• Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;
• Recent hospital admission (\<4 weeks prior to the start of the study);
• Lung malignancy in the previous 5 years;

Other illness

• Allergy or intolerance to components of the study product;
• Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);
• Patients with terminal illness;
• Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;
• Recent diagnosis of cerebral conditions (\<1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;
• Any medical condition that significantly interferes with digestion and/or gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.
• Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);
• Patients with terminal illness;
• Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;
• Recent diagnosis of cerebral conditions (\<1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;
• Any medical condition that significantly interferes with digestion and/or gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.
• Diagnosis of any chronic lung disease.

Age

• Age \<18 years;
• Age \<18 years;

Other

• Not willing or not able to quit vitamin D or fatty acid supplement intake;
• Temporary antibiotics use in the last 4 weeks;

• COPD patients with moderate to very severe disease stage according to GOLD criteria (i.e. GOLD stage II-IV);
• Medically stable.
• Forced expiratory volume in 1 second/Forced vital capacity \> 0.7;
• Medically stable.